

Patient Name : MR. PRASHANT	Registration Time : Oct 26, 2024, 10:43 a.m.
Age / Gender : 39 years / Male	Receiving Time : Oct 26, 2024, 10:44 a.m.
MR No. / IPD No. : /	Reporting Time : Oct 26, 2024, 12:55 p.m.
Patient Type / Bed No. : /	 241026081
Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)	Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)
	Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

HAEMATOLOGY

Complete Haemogram - Hb RBC count and indices, TLC, DLC, PLATELET, ESR.

Hemoglobin (Hb) Method : Whole Blood, SLS-haemoglobin	14.7	g/dL	13.0 - 17.0
Erythrocyte (RBC) Count Method : Whole Blood, DC detection	4.97	x 10 ⁶ /uL	4.5 - 5.5
HCT Method : Whole Blood, RBC pulse height detection	45.1	%	42 - 52
Mean Cell Volume (MCV) Method : Whole Blood, Electrical Impedence	90.7	fL	78 - 100
Mean Cell Haemoglobin (MCH) Method : Whole Blood, Calculated	29.6	pg	27 - 31
Mean Corpuscular Hb Conc. (MCHC) Method : Whole Blood, Calculated	32.6	g/dL	32.0 - 35.0
Red Cell Distribution Width (RDW) CV Method : Whole Blood, Calculated	13.5	%	11.5 - 14.0
Total Leucocytes (WBC) Count Method : Whole Blood, Flow cytometry	6.5	x 10 ³ /uL	4 - 10
DLC (Differential Leucocytes Count)			
Neutrophils Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	64.7	%	40 - 80
Lymphocytes Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	27.8	%	20 - 40
Monocytes Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	5.8	%	2 - 10
Eosinophils Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	1.4	%	1 - 6
Basophils Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	0.3	%	0 - 2
Absolute Neutrophil Count Method : Whole Blood, Calculated	4.21	x 10 ³ /uL	2.0 - 7.0
Absolute Lymphocyte Count Method : Whole Blood, Calculated	1.81	x 10 ³ /uL	1 - 3

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:55 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--


Test Description	Value(s)	Unit(s)	Reference Range
Absolute Monocyte Count Method : Whole Blood, Calculated	0.38	x 10 ³ /uL	0.2-1.0
Absolute Eosinophil Count Method : Whole Blood, Calculated	0.09	x 10 ³ /uL	0.02 - 0.5
Absolute Basophils Count Method : Whole Blood, Calculated	0.02	x 10 ³ /uL	0.02 - 0.1
Platelet Count Method : Whole Blood, DC Detection	142	x 10 ³ /uL	150 - 450
ESR - Erythrocyte Sedimentation Rate Method : Whole blood , Modified Westergren Method	46	mm/hr	<10

Interpretation:

It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever,. It is also increased in multiple myeloma, hypothyroidism.

Tests done on Automated Six Part Cell Counter.

****END OF REPORT****




Dr.Artri Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 03:26 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
<u>CLINICAL PATHOLOGY</u>			
<u>Urine Glucose (Fasting & PP)</u>			
Glucose Fasting (Urine) Method : Oxidase Reaction/ Manual	Negative		Negative
Glucose Post Prandial (Urine) Method : Oxidase Reaction/ Manual	Negative		Negative

END OF REPORT



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:12 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

HAEMATOLOGY

Blood Group (ABO)

Blood Group	"B"		
Method : Forward and Reverse by Slide method			
RH Factor	Positive		


Methodology

This is done by forward and reverse grouping by slide agglutination method.

Interpretation

Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B antigen expression and the isoagglutinins are fully developed (2–4 years).

END OF REPORT



Dr. Arti Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MR. PRASHANT

Age / Gender : 39 years / Male

MR No. / IPD No. : /

Patient Type / Bed No. : /

Referred By : ARCOFEMI HEALTH CARE
 PVT.LIMITED (MEDIWHEEL)

Registration Time : Oct 26, 2024, 10:43 a.m.

Receiving Time : Oct 26, 2024, 10:44 a.m.

Reporting Time : Oct 26, 2024, 12:12 p.m.


241026081

Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT.
 LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY

LFT (Liver Function Test,Serum)

Total Protein Method : Biuret Method	7.6	g/dL	6.4-8.3
Albumin Method : Bromocresol Green	4.3	g/dL	3.5 - 5.2
Globulin Method : Calculated	3.30	g/dL	1.8 - 3.6
A/G Ratio Method : Calculated	1.30	ratio	1.2 - 2.2
SGOT Method : IFCC without Pyridoxal Phosphate	24	U/L	0 to 40
SGPT Method : IFCC without Pyridoxal Phosphate	27	U/L	0 to 41
Alkaline Phosphatase-ALP Method : PNP AMP Kinetic	113	U/L	40-129
GGT-Gamma Glutamyl Transferase Method : IFCC	10	U/L	0 to 60
Bilirubin Total Method : Colorimetric Diazo Method	0.60	mg/dL	0.0-1.20
Bilirubin - Direct Method : Colorimetric Diazo Method	0.20	mg/dL	Adults and Children: < 0.30
Bilirubin - Indirect Method : Calculated	0.40	mg/dL	0.1 - 1.0

Interpretation :

SGOT/ SGPT: Increased in Acute viral hepatitis, Biliary tract obstruction (cholangitis, choledocholithiasis), Alcoholic hepatitis and Cirrhosis, liver abscess, metastatic or primary liver cancer; non-alcoholic steatohepatitis; right heart failure. Decreased in Pyridoxine (vit B6) deficiency.

Alkaline Phosphatase: Increased in Obstructive hepatobiliary disease, Bone disease (physiologic bone growth, Paget disease, Osteomalacia, Osteogenic sarcoma, Bone metastases), Hyperparathyroidism, Rickets, Pregnancy (third trimester). Decreased in Hypophosphatasia.

GGT: Increased in Liver disease Acute viral or toxic hepatitis, Chronic or subacute hepatitis, Alcoholic hepatitis, Cirrhosis, Biliary tract obstruction.

Protein: Moderate-to-marked hyperproteinemia maybe due to multiple myeloma and other malignant paraproteinemias, Hypoproteinemia may be due to decreased production or increased protein loss.


Albumin: Increased in Dehydration, Shock, Hemoconcentration. Decreased in hepatic synthesis(Chronic liver disease, malnutrition, malabsorption, malignancy), Increased losses (Nephrotic syndrome, Burns, Trauma, Hemorrhage with fluid replacement, acute or chronic glomerulonephritis), Hemodilution (pregnancy, CHF) and Drugs (estrogens).

Bilirubin: A substance produced during the normal breakdown of red blood cells.Elevated levels of bilirubin (jaundice) might indicate liver damage or disease or certain types of anemia.

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:12 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

END OF REPORT



Dr.Artri Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:12 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--


Test Description	Value(s)	Unit(s)	Reference Range
BIOCHEMISTRY			
Lipid Profile,Serum			
Cholesterol-Total Method : Enzymatic Colorimetric,CHOD-POD	185	mg/dL	Desirable: <= 200 Borderline High: 201-239 High: > 239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.
Triglycerides Method : Enzymatic Colorimetric ,GOD-POD	131	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500
Cholesterol-HDL Direct Method : CHOD-POD (Homogenous Enzymatic)	40	mg/dL	No Risk - >55 mg/dL Moderate risk - 35-55 mg/dL High risk - < 35 mg/dL
LDL Cholesterol Method : Calculated	118.80	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190
Non - HDL Cholesterol, Serum Method : Calculated	145	mg/dL	Desirable: < 130 mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL
VLDL Cholesterol Method : Serum, Calculated	26.20	mg/dL	0 - 30
CHOL/HDL RATIO Method : Calculated	4.63	Ratio	3.5 - 5.0
LDL/HDL RATIO Method : Calculated	2.97	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0
HDL/LDL RATIO Method : Calculated	0.34	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0

Note: 10-12 hours fasting sample is required.

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:12 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

END OF REPORT



Dr.Artri Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:12 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY

KFT (Renal Function Test,Serum)

Urea Method : kinetic (urease-GLDH)	24	mg/dL	16.6-48.5
BUN Method : Calculated	11.21	mg/dL	6-20
Creatinine Method : Kinetic Colorimetric (Jaffe Method)	0.90	mg/dL	0.70-1.30
Uric Acid Method : Enzymatic Colorimetric: Uricase-POD	7.4	mg/dL	3.4-7.0

Interpretation :

Urea:- Increased in renal diseases,urinary obstructions, shock, congestive heart failure .Decreased in liver failure and pregnancy.

Creatinine :- Elevated in renal dysfunction, reduced renal blood flow shock, dehydration, Congestive heart failure, Diabetes Acromegaly. Decreased levels are found in Muscular Dystrophy.


Uric acid:- Increased in Gout, Arthritis, impaired renal functions and starvation.Decreased in Wilson's disease, Fanconis Syndrome and Yellow Atrophy of Liver.

Sodium:-Increased in Excessive dietary salt ,Diuretic therapy,Adrenal insufficiency,Salt-wasting nephropathy and Vomiting.Decreased levels are seen in Hyperaldsteronism ,Hyponatremia,Prerenal Azotemia,Renal Failure and Glomerulonephritis.

Potassium:- Low levels is common in vomiting, diarrhea, alcoholism, and folic acid deficiency. Increase level are seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid potassium infusion.

Chloride:- Increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis, diabetes insipidus, adrenocortical hyperfuction. Decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis.

END OF REPORT


Dr.Artri Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:12 p.m.  241026081F Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY


Glucose (Fasting)

Glucose Fasting Method : Plasma,Enzymatic Hexokinase	96	mg/dL	Normal: 72-106 Impaired Tolerance: 100-125 Diabetes mellitus: ≥ 126 (on more than one occasion) (American diabetes association guidelines 2018)
--	----	-------	--

Interpretation

Glucose is the major carbohydrate present in the peripheral blood. Oxidation of glucose is the major source of cellular energy in the body. The concentration of glucose in blood is controlled within the narrow limits by many hormones, the most important of which are produced by the pancreas. The most frequent cause of hyperglycaemia is diabetes mellitus resulting from deficiency in insulin secretion or action. These include pancreatitis, thyroid dysfunction, renal failure, and liver disease. Hypoglycaemia is less frequently observed. A variety of conditions may cause low blood glucose levels such as insulinoma, hypopituitarism, or insulin induced hypoglycaemia.

END OF REPORT


Dr.Artri Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 02:15 p.m. Reporting Time : Oct 26, 2024, 02:55 p.m.  241026081P Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY

Glucose (PP)


Blood Glucose-Post Prandial	71	mg/dL	70 - 140
------------------------------------	----	-------	----------

Method : Plasma, Enzymatic Hexokinase

Interpretation

Glucose is the major carbohydrate present in the peripheral blood. Oxidation of glucose is the major source of cellular energy in the body. The concentration of glucose in blood is controlled within the narrow limits by many hormones, the most important of which are produced by the pancreas. The most frequent cause of hyperglycaemia is diabetes mellitus resulting from deficiency in insulin secretion or action. These include pancreatitis, thyroid dysfunction, renal failure, and liver disease. Hypoglycaemia is less frequently observed. A variety of conditions may cause low blood glucose levels such as insulinoma, hypopituitarism, or insulin induced hypoglycaemia.

END OF REPORT



Dr.Artri Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012

<p>Patient Name : MR. PRASHANT</p> <p>Age / Gender : 39 years / Male</p> <p>MR No. / IPD No. : /</p> <p>Patient Type / Bed No. : /</p> <p>Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)</p>	<p>Registration Time : Oct 26, 2024, 10:43 a.m.</p> <p>Receiving Time : Oct 26, 2024, 10:44 a.m.</p> <p>Reporting Time : Oct 26, 2024, 12:12 p.m.</p> <div style="text-align: center;">  241026081 </div> <p>Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)</p> <p>Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)</p>
---	---



Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

BIOCHEMISTRY

Glycated Hb (HbA1c)

HbA1c (Glycated Hemoglobin)	5.4	%	Non-Diabetic : <5.7
Method : EDTA Whole blood, HPLC, NGSP certified			Pre Diabetes : 5.7 - 6.4
			Diabetes : ≥ 6.5


Estimated Average Glucose : 108.28 mg/dL

Interpretations

- HbA1c has been used as one of the key biomarkers in identifying patients with Diabetes . American Diabetes Association (ADA) and several clinical groups have endorsed utility of HbA1c testing using a cut off value of 6.5%. The average concentration of blood glucose(eBG) is reflected in this test over a period of the past three months.
- Therapeutic goals for monitoring Diabetes.
 - Goal of therapy < 7% HbA1c.
 - Action suggested > 8 % HbA1c
- Patients with shortened red cell survival(hemolytic disease), recent significant blood loss have lower HbA1c values .
- High HbA1c is associated with Iron deficiency ,patients with polycythemia or post splenectomy.

Note : The presence of hemoglobin variants can interfere with measurement of HbA1c.

END OF REPORT


Dr. Arti Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:55 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

IMMUNOLOGY

Thyroid Function Test (Free),Serum

Free triiodothyronine (FT3) <small>Method : ECLIA</small>	1.28	pg/ml	2.0 - 4.40
Free Thyroxine (FT4) <small>Method : ECLIA</small>	7.75	ng/dL	0.93 - 1.70
TSH-Ultrasensitive <small>Method : ECLIA</small>	5.48	uIU/mL	0.27-4.20

Interpretation

The Biological reference interval provided is for Adults.
 For age specific reference interval, please refer to the table given below.

TSH	T3/FT3	T4/FT4	Interpretation
High	Normal	Normal	Subclinical Hypothyroidism
Low	Normal	Normal	Subclinical Hyperthyroidism
High	High	High	Secondary Hypothyroidism
Low	High/Normal	High/Normal	Hyperthyroidism
Low	Low	Low	Non Thyroidal illness/Secondary Hyperthyroidism


TSH (mU/mL)			
Children	New Born	0.7	15.2
	6 days - 3 Months	0.72	11
	4 -12 Months	0.73	8.35
	1-6 Years	0.7	5.97
	7-11 Years	0.6	4.84
	12-20 years	0.51	4.3
Adults		0.27	4.2

TSH levels are subjected to circadian variation, rising several hours before the onset of sleep, reaching peak levels between 11 pm and 6 am. Nadir concentration are observed during the afternoon. diurnal variation in TSH levels is approx 50%+/-, hence time of the day can influence the measured serum concentration.

Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:55 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

END OF REPORT



Dr.Artri Tripathi
MD Pathology
Chief Consultant, Pathology
DMC No: 43012

Patient Name : MR. PRASHANT

Age / Gender : 39 years / Male

MR No. / IPD No. : /

Patient Type / Bed No. : /

Referred By : ARCOFEMI HEALTH CARE
 PVT.LIMITED (MEDIWHEEL)

Registration Time : Oct 26, 2024, 10:43 a.m.

Receiving Time : Oct 26, 2024, 10:44 a.m.

Reporting Time : Oct 26, 2024, 12:55 p.m.


241026081

Panel : Dr Arcofemi Health Care PVT.limited (MediWheel)

Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

CLINICAL PATHOLOGY

Urine (RE/ME)

Physical Examination :

Volume Method : Visual Observation	40		mL
Colour Method : Visual Observation	Pale Yellow		Pale Yellow
Transparency (Appearance) Method : Visual Observation	Clear		Clear
Deposit Method : Visual Observation	Absent		Absent
Reaction (pH) Method : Double Indicator method	6.0		4.5 - 8.0
Specific Gravity Method : Ionic Concentration	1.015		1.010 - 1.030

Chemical Examination (Dipstick Method) Urine

Urine Protein Method : Protein Ionisation/ Manual	Absent		Absent
Urine Glucose (sugar) Method : Oxidase Reaction/ Manual	Absent		Absent
Blood (Urine) Method : Peroxidase Reaction	Absent		Absent

Microscopic Examination Urine

Pus Cells (WBCs) Method : Microscopy	2 - 4	/hpf	0 - 5
Epithelial Cells Method : Microscopy	1 - 2	/hpf	0 - 4
Red blood Cells Method : Microscopy	Absent	/hpf	Absent
Crystals Method : Microscopy	Absent		Absent
Cast Method : Microscopy	Absent		Absent
Yeast Cells Method : Microscopy	Absent		Absent
Amorphous Material Method : Microscopy	Absent		Absent


Patient Name : MR. PRASHANT Age / Gender : 39 years / Male MR No. / IPD No. : / Patient Type / Bed No. : / Referred By : ARCOFEMI HEALTH CARE PVT.LIMITED (MEDIWHEEL)		Registration Time : Oct 26, 2024, 10:43 a.m. Receiving Time : Oct 26, 2024, 10:44 a.m. Reporting Time : Oct 26, 2024, 12:55 p.m.  241026081 Panel : Dr Arcofemi Health Care PVT.limited (MediWheel) Client Code : ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
Bacteria	Absent		Absent
Method : Microscopy			
Others	Absent		

Remarks:-

Epithelial cells	Urolithiasis bladder carcinoma or hydronephrosis ,ureteric stents or bladdercatheters for prolonged periods of time.
Granular casts	Low intratubular pH,high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration,acute congestive heart failure, renal diseases.
Calcium Oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of VitaminC, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit(A verrhoa carambola)or its juice
Uric acid	Artharitis
Bacteria	Urinary infection when present in significant numbers and with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

END OF REPORT



Dr.Artri Tripathi
 MD Pathology
 Chief Consultant, Pathology
 DMC No: 43012



Name Mrs. Prashant Age 34y Sex M
Deptt. Ref by Date 26/10/24
M.R. No. H/O Drug Allergy-Y/N

Deptt. of General & Laparoscopic Surgery

Dr. Vinay Sabharwal

M.B.B.S., M.S., FICA
Hon. Surgeon to Fmr. President of India
Sir Ganga Ram Hospital
Sr. Member : Association of Surgeons of India
Indian Association of Gastro. Endo Surgeons
Indian Hernia Society
Association of Min. Access Surgeons of India
E-mail: drvinay@jmh.in
Website: www.drvinay@sabharwal.com
DMC No. 4687

Vinc 6/9
6/6
Near NB
NB

Dr. Malvika Sabharwal

MBBS, DGO, F.I.C.O.G., Dipl. Endo. Surgery (USA)
Awarded Padmashri by the President of India
Chief Dept. of Gynae, Laparoscopic, Endoscopy Surgery
President, Delhi Gynae Endoscopy Society (2018)
Founder Chairperson: Indian Ass. of Gynae. Endoscopists
International Society of Gynae. Laparoscopists
American Association Gynae. Laparoscopy
Federation of obst. & Gynae. Societies of India
International College of Obst. & Gynae
E-mail: drmalvika@jmh.in
Website: drmalvika@sabharwal.com
DMC No. 4686

Ant. Segment (B70-NAB)

Fundus (B70-NAB)

Colour vision on Ishihara charts
- Normal

Deptt. of E.N.T.

Dr. R.K. Trivedi

M.B.B.S., D.L.O., M.S. (E.N.T.)
Senior Consultant
D.M.C. No.: 12647

Dr. Rajeev Nangia

M.B.B.S., M.S. (E.N.T.)
Senior Endoscopic Surgeon
DMC No. 4681

Deptt. of Ophthalmology

Dr. Ashwani Seth

M.B.B.S., M.S.
Senior Consultant Eye Surgeon
D.M.C. No.: 13702

Dr. S.C. Pahwa

M.B.B.S., M.S. (Ophth)
Eye Surgeon
D.M.C. No.: 8424

[Signature]
Dr. S. C. PAHWA
M.B.B.S. M.S. (Ophth)
EYE SURGEON
Reg. No. 8424 (D.M.C.)

[Signature]
Dr. S. C. PAHWA
M.B.B.S. M.S. (Ophth)
EYE SURGEON
Reg. No. 8424 (D.M.C.)

Adv - Refraction.

Deptt. of Dentistry

Dr. Varun Aggarwal

B.D.S., M.D.S., CAIC, M.I.D.A.
Consultant Implantologist
& Unit Head

Dr. Neha Gupta

B.D.S., PGCHM, F.I.C.D., M.I.D.A.
Senior Consultant
Deptt. of Dentistry

Treatment Adv for days Next followup Visit on



Name Mr. Rakeshant Age Sex.....
Ref by Date.....

M.R. No. H/O Drug Allergy - Yes / No

Deptt. of Medicine

Dr. Vineet Sabharwal
M.B.B.S., M.D. (MED)
Senior Physician
DMC No.: 3860

Dr. Rakesh Sharma
M.B.B.S., M.D. (MED)
Senior Consultant Physician
DMC No.: 5671

Dr. Vishal Garg
M.B.B.S., MD (Internal Medicine)
Senior Consultant Physician
Post Graduate in Diabetes (Boston, USA)
Thyroid Specialist (ATS, USA)
DMC No.: 50003

Dr. Pankaj Kumar
M.B.B.S. (Hons), DTCD
Consultant Physician,
Pulmonologist & Intensivist
DMC No.: 18751

Dr. Glossy Sabharwal
MBBS, MD Radio-Diagnosis
Clinical and Interventional Radiologist
Maternal-Fetal Medicine Specialist
Fetal Medicine Foundation Certified (UK)
Fellow - Breast Interventional Imaging (Paris)
Ex - Jt. Secretary IRIA (Delhi)
Harvard University Certified
Yale School of Medicine Certified
Certified Reproductive Health Specialis
Distinction Holder MD Radiology
ECFMG Certified (USA)
Young Investigator Scholar (AOCC - Japan)

Member
ISUOG (USA)
IRIA (India)
SFM (UK)
IFUMB (India)
RSNA (USA)
e-mail: docglossy@gmail.com
Website: www.drglossy.in
Mob.: 9811020477, DMC No. 58599

Dr. Laxmi Kant Tomar
MBBS, MD (Medicine)
DM (Neurology)
DMC NO- DMC/R/5022

Dr. Jatin Anand
M.D. (Psychiatry)
DMC No.: 61376

Dr. Mudit Gupta
MBBS
DNB (General Medicine)
DM (Nephrology)
DMC No.: 34678

Dr. Avinash Bansal
MBBS, MD (Medicine)
DM (Cardiology) SGPIMS
DMC- 33007

Dr. Sandeep Bhagat
MBBS
MD (General Medicine)
DNB (Gastro)
DMC No.: 16977

Dr. Sandeep Garg
MBBS
MD (Pulmonary Medicine)
DMC No.: 52901

Dr. Nikhil Sharma
MBBS, DDV
Consultant Dermatology & Cosmetology
DMC No.: 27578

BP → 110/60

PR → 59b/m

SpO2 = 99%

Temp = 97.1 F

W = 87.8 kg

According to the preliminary reports patient is vitally stable

Plan

- Repeat thyroid profile after 15 days

- exercise

- healthy balanced diet

SYED NAZMUS SAQUIE
SENIOR MEDICAL OFFICER
DMC - DMC/R/1184
JEEWAN MALA HOSPITAL
NEW DELHI - 110005

Treatment Adv for days - Next Followup Visit on.....

67/1, New Rohtak Road, New Delhi-110 005 (India) Tel.: 47774141, 9212167895
E-mail.: info@jmh.in Website : www.jmh.in



Name PRASHANT Age 39/8 Sex M
 Deptt..... Ref by Date 25/1/24
 M.R. No. H/O Drug Allergy-Y/N.....

Deptt. of General & Laparoscopic Surgery

Dr. Vinay Sabharwal

M.B.B.S., M.S., FICA
 Hon. Surgeon to Fmr. President of India
 Sir Ganga Ram Hospital
 Sr. Member : Association of Surgeons of India
 Indian Association of Gastro. Endo Surgeons
 Indian Hernia Society
 Association of Min. Access Surgeons of India
 E-mail: drvinay@jmh.in
 Website: www.drvinay@sabharwal.com
 DMC No. 4687

For routine SNT Examination

Dr. Malvika Sabharwal

MBBS, DGO, F.I.C.O.G., Dipl. Endo. Surgery (USA)
 Awarded Padmashri by the President of India
 Chief Dept. of Gynae, Laparoscopic, Endoscopy Surgery
 President, Delhi Gynae Endoscopy Society (2018)
 Founder Chairperson: Indian Ass. of Gynae. Endoscopists
 International Society of Gynae. Laparoscopists
 American Association Gynae. Laparoscopy
 Federation of obst. & Gynae. Societies of India
 International College of Obst. & Gynae
 E-mail: drmalvika@jmh.in
 Website: drmalvika@sabharwal.com
 DMC No. 4686

For Normal SNT Examination

Deptt. of E.N.T.

Dr. R.K. Trivedi

M.B.B.S., D.L.O., M.S. (E.N.T.)
 Senior Consultant
 D.M.C. No.: 12647

Dr. Rajeev Nangia

M.B.B.S., M.S. (E.N.T.)
 Senior Endoscopic Surgeon
 DMC No. 4681

Deptt. of Ophthalmology

Dr. Ashwani Seth

M.B.B.S., M.S.
 Senior Consultant Eye Surgeon
 D.M.C. No.: 13702

Dr. S.C. Pahwa

M.B.B.S., M.S. (Ophth)
 Eye Surgeon
 D.M.C. No.: 8424

Deptt. of Dentistry

Dr. Varun Aggarwal

B.D.S., M.D.S., CAIC, M.I.D.A.
 Consultant Implantologist
 & Unit Head

Dr. Neha Gupta


B.D.S., PGCHM, F.I.C.D., M.I.D.A.
 Senior Consultant
 Deptt. of Dentistry


Treatment Adv for.....days Next followup Visit on.....

Atrial Rate: _____
 Ventricular Rate: _____
 Rhythm _____
 Axis _____
 P. Wave _____
 P.R. Interval _____
 QRS Duration _____
 Q.T. Duration _____
 Q.T. Interval _____
 Conclusion _____

ST Segment _____
 T. Wave _____
 -Others _____

Signature _____
 Doctor I/C _____

Normal ST-segment






Ashutosh

29/10/2024 at 5:07 pm





Mr Prashant
Date: October 26, 2024

Age: 39 Y/ Sex: M

ULTRASOUND WHOLE ABDOMEN

Limited visibility due to excessive bowel gases noted in abdomen.

Liver is normal in size and shows diffuse increase in echogenicity s/o grade-I fatty infiltration. No focal lesion seen in the liver.
Intrahepatic bile ducts and portal radicals are normal in caliber.
Portal vein is normal in caliber

Gall bladder does not show any evidence of cholecystitis or cholelithiasis.

- CBD- proximal visualized part: - is not dilated.
- CBD- Mid and distal segment is obscured due to technical limitation.
- Central IHBR:- normal in caliber

Both kidneys are of normal size, shape and echopattern. No calculus, growth or hydronephrotic changes seen in either kidney. The parenchymal thickness is normal & cortico-medullary differentiation is well maintained.

Spleen is normal in size and echotexture.
Pancreas does not show any pathology.

Urinary bladder is distended and shows no mural or intraluminal pathology.
Prostate is normal in size and shape. No focal lesion is seen.
No free fluid or pelvic collection seen.

Please correlate clinically

[Signature]
DR. GLOSSY B SABHARWAL, MD
CONSULTANT RADIOLOGIST

This report is only a professional opinion and it is not valid for medico-legal purposes.

JEEWAN MALA HOSPITAL PVT. LTD.

67/1, New Rohtak Road, New Delhi-110 005 (India) Tel.: 47774141, 9212167895.
E-mail: info@jmh.in Website: www.jmh.in

GSTIN No. 07AABCJ0920A1ZD / CIN No. U74899DL1991PTC043833